Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Green-lipped mussel (GLM), derived from the species *Perna canaliculus* native to New Zealand, is a dietary supplement primarily used to manage inflammatory conditions, most notably osteoarthritis. [2, 5] Its therapeutic effects are attributed to a unique and complex profile of lipids, including various omega-3 polyunsaturated fatty acids (PUFAs) like EPA, DHA, and the rare eicosatetraenoic acid (ETA), as well as furan fatty acids. [3, 6, 21] These compounds are believed to exert anti-inflammatory effects by inhibiting key enzymes in the arachidonic acid cascade, specifically cyclooxygenase (COX) and 5-lipoxygenase (LOX). [3, 13] Clinical studies in humans have demonstrated that GLM extracts can reduce joint pain, stiffness, and improve mobility in patients with knee osteoarthritis. [1, 4] Some research also suggests it may improve gastrointestinal function in these patients, potentially by modulating the gut microbiota. [12] In addition to human use, green-lipped mussel is widely used in veterinary medicine to alleviate symptoms of arthritis in dogs and other animals. [6, 14]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on green-lipped mussel.